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Abstract
Introduction. Contingency management interventions are among the most efﬁcacious psychosocial interventions in promoting abstinence from smoking, alcohol and substance use. The aim of this study was to assess the beliefs and objections towards
contingency management among patients in UK-based drug and alcohol services to help understand barriers to uptake and
support the development and implementation of these interventions. Methods. The Service User Survey of Incentives was
developed and implemented among patients (N = 181) at three UK-based drug and alcohol treatment services. Descriptive
analyses were conducted to ascertain positive and negative beliefs about contingency management, acceptability of different target behaviours, incentives and delivery mechanisms including delivering incentives remotely using technology devices such as
mobile telephones. Results. Overall, 81% of participants were in favour of incentive programs, with more than 70% of
respondents agreeing with the majority of positive belief statements. With the exception of two survey items, less than a third of
participants agreed with negative belief statements. The proportion of participants indicating a neutral response was higher for
negative statements (27%) indicating greater levels of ambiguity towards objections and concerns regarding contingency management. Discussion and Conclusions. Positive beliefs towards contingency management interventions were found,
including high levels of acceptability towards a range of target behaviours, incentives and the use of technology devices to
remotely monitor behaviour and deliver incentives. These ﬁndings have implications for the development and implementation
of remote contingency management interventions within the UK drug treatment services. [Getty C-A, Weaver T, Lynskey
M, Kirby KC, Dallery J, Metrebian N. Patients’ beliefs towards contingency management: Target behaviours,
incentives and the remote application of these interventions. Drug Alcohol Rev 2021]

Key words: contingency management, substance use, acceptability, beliefs, survey.

Introduction
Contingency management (CM) interventions, based
on the scientiﬁc principles of operant conditioning,
involve the application of positive reinforcement contingent upon behaviour change. CM is among the
most efﬁcacious psychosocial interventions in promoting abstinence from smoking, alcohol and illicit drugs
[1–7]. While CM has a strong evidence base, acceptability of these interventions among staff and patients
is vital. Capturing their views and attitudes can support
CMs implementation into routine service provision,
ensuring the development and delivery of interventions

that are consistent with patients’ and staff’s idea of
appropriate treatment.
While prior research, predominately surveying treatment providers in the USA, demonstrates support for
CM with the majority endorsing favourable opinions
towards these interventions [8,9], several concerns
have been highlighted. These include issues related to
the practicality of implementing CM, lack of sustained
treatment effects and economic evaluations, and ethical objections towards the use of ﬁnancial incentives to
reinforce behaviour change [8–14]. These factors
might be impeding the uptake and implementation of
CM within clinical practice in the UK and
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international addiction services and need to be
addressed prior to implementation efforts.
In addition, patients’ beliefs towards CM have not
been widely investigated. Research has been limited to
surveys examining acceptability of study procedures
among patients in receipt of CM in the USA [15–19]
and a small UK-based qualitative investigation [20].
These studies found that patients view CM as a motivating and positive tool to facilitate recovery and the
monitoring of behaviours and ﬁnancial incentives are
strengths of the intervention [16]. However, these
beliefs are most likely to be affected by multiple contextual factors. For example, there are many differences between the UK and US health-care systems
and understanding acceptability among patients within
UK substance use services might further illuminate
beliefs in a UK-speciﬁc context. Additionally, it will be
helpful to assess if patient’s beliefs and objections
towards CM are associated with different patient characteristics (e.g. length of time in treatment and age) as
associations between positive beliefs and several characteristics of treatment providers have previously been
found [8,21].
The use of technology to facilitate the application of
CM to improve health-related behaviours such as
abstinence is a growing area of research [22]. Remote
applications of CM have been developed to enhance
the reach of these interventions, enabling patients to
stay in contact with services when engagement is variable or intermittent over a long period [23]. Technology might optimise the application of reinforcement
principles, monitoring and reinforcing the target
behaviour more frequently than is otherwise possible
[22,24]. A meta-analysis of mobile telephone-delivered
CM [25] and more recent evaluation studies [19,26–
30] suggest these interventions are effective in generating positive behaviour change. However, the platforms
upon which these interventions can be implemented
might vary in their appropriateness or acceptability to
the patient population. Research exploring patients’
acceptability towards these modern modalities (which
are typically automated with limited human interaction) has been conﬁned to explorations of acceptability
among participants in the context of existing studies in
the USA [31–33].
The aim of this study was to explore beliefs towards
CM among patients receiving treatment for substance
use disorders (SUD) in UK addiction services. Speciﬁc objectives included assessing: beliefs and objections towards CM; acceptability of social and tangible
rewards; acceptability of targeting different substance
related behaviours; and acceptability of using technology to remotely monitor behaviour and deliver incentives. The associations between patient characteristics
and beliefs were also explored.

Method
Participants
Participants were patients receiving treatment for SUDs
in three London drug services. The clinics are managed
by the South London & Maudsley National Health Service Foundation Trust who provides the widest range of
National Health Service mental health services in the
UK, offering specialist in-clinic and outpatient services
to help patients with SUD in reducing or stopping their
use and minimising the associated harm. Participants
were eligible to take part if they were receiving treatment, ﬂuent in English and over the age of 18.

Procedure
Patients were approached by the researcher while
waiting in the clinic reception for their appointment,
informed about the study and provided with an information sheet. Following informed consent, the questionnaire was provided to the participant and completed
at the clinic (with the researcher if requested). To
encourage participation, entry to a prize draw to win a
£50 gift voucher was offered.

Service User Survey of Incentives
The questionnaire was created in collaboration with the
author of the Provider Survey of Incentives (PSI): a
44-item scale assessing beliefs held by treatment providers
regarding CM [8]. The research team created a pool of
question items from the PSI and rated each item for importance on a 5-point scale. Overlapping items and those rated
as low importance to service users were removed. Question
items were selected based on their relevance to a patient
population and those speciﬁc to health-care providers were
omitted. Language was modiﬁed for a UK patient group.
Authors of the PSI indicated that the structure of the questionnaire of asking the same questions for social and tangible incentives separately could have created a contrast
effect, such that one type of incentive would be favoured
over the other. This limitation was taken into consideration
and tangible incentives were focused on. The Service User
Survey of Incentives (SUSI) was developed, consisting of
18-items categorised into four themes: limitations of incentive programs, ethical/moral objections, negative side effects
and positive opinions regarding incentives.
The questionnaire consisted of four parts and provided a brief description of CM to ensure participants
were aware of its key features, including frequency and
delivery of the reinforcer contingent on objective veriﬁcation of the target behaviour. Part A contained two
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questions to measure awareness and experience of CM
incentives. Part B contained the 18-item SUSI to
ascertain beliefs and objections towards CM. Part C
contained ﬁve sets of questions: two speciﬁc to attitudes towards different types of rewards and target
behaviours, while three questions were speciﬁc to the
remote application of CM. Participants were required
to indicate their level of agreement with each survey
item on a 5-point Likert scale [(strongly) disagree,
neutral, (strongly) agree]. Part D contained questions
regarding basic demographics and treatment history.

3

Results
Participant demographics and substance use characteristics
Participants (N = 181) were recruited between
November 2019 and March 2020. Participants were
male (63%), White (74%), with a median age of
45 years (interquartile range 53–37). Participants were
currently receiving treatment for a range of substances,
heroin (54%) and alcohol (39%) being the two most
reported. Time in treatment ranged from 1 month to
50 years (median 5, interquartile range 15–0.9)
(Table 1).

Data analysis
The proportion of participants indicating agreement,
disagreement or neutral responses to the individual
items were calculated for descriptive purposes. Items
on the SUSI were categorised according to the four
themes: positive beliefs (items 1, 3, 5, 10, 11, 12,
15, 16, 17 and 18), limitations of incentive programs
(items 6, 9 and 14), ethical/moral objections (items
2, 7 and 8) and negative side effects (items 4 and 13)
with summary scores pooled for descriptive purposes.
Variables were recoded, grouping levels of agreement
(strongly disagree/disagree and strongly agree/agree) to
aid comparison across items and subscales.
Positive and negative belief items were grouped, summary scores calculated and associations with participant
characteristics explored. Reliability analyses were carried
out on the two subscales to assess the internal validity
and appropriateness of congregating survey items.
Cronbach’s alpha showed the positive beliefs subscale
(10 items: 1, 3, 5, 10, 11, 12, 15, 16, 17, 18) and the
negative beliefs subscale (8 items: 2, 4, 6, 7, 8, 9, 13, 14)
reached good reliability; α = 0.88, α = 0.79, respectively.
Inter-item correlations indicated that all items are worthy
of retention, resulting in a decrease in the alpha if
deleted. Missing values were coded as missing in SPSS
and analyses were conducted using the available data.
Participants were divided by age, and into four
groups based on their length of time in treatment:
(<1 year, 1–5 years, 5–10 years, >10 years). Pearson
chi-square analyses examined associations between
awareness and experience of CM, speciﬁc participant
characteristics and the repeated dependent variable
(SUSI subscale score) to determine if they were associated with differences in beliefs.

Ethical considerations
The project received ethical approval from the London
Chelsea National Health Service Research Ethics
Committee (19/LO/1590).

Mobile phone ownership
Mobile phone ownership was high (96%). Of those, 85%
owned smartphones and 56% had a monthly contract
plan, while 27% reported to changing their mobile number in the last year. Most participants (94%) reported that
they would be comfortable with their treatment provider
contacting them on their mobile phone, but only 31% said
they would be comfortable with the use of geo-location for
treatment purposes.

Awareness and experience of incentive interventions
Overall, 33% of participants reported being aware of
CM interventions. However, only 8% reported they
had experienced it.

Positive and negative beliefs towards CM
Table 2 shows the percentages of participants indicating agreement, disagreement or neutral responses to
individual survey items.
Positive beliefs. Overall, high proportions of participants agreed with statements expressing positive beliefs
regarding CM, with 81% indicating that they would be
‘in favour of incentive programmes’. With the exception
of 2 of the 10 survey items, over 70% of respondents
agreed with all positive belief statements. Statements
that were among the most highly endorsed were that
‘incentives are useful if they reward service users for fulﬁlling health care goals…’ and ‘incentives are more
likely to have positive effects… than they are to have
negative effects’. Less endorsed statements included
‘incentives are good for the service user-recovery worker
relationship’ and ‘incentives can be useful whether or
not they address the underlying reasons for engaging in
unhealthy behaviour’, with 65% and 48% of
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Table 1. Participant characteristics
Variable
Age, years
Gender
Ethnicity

Employment status

Accommodation status

Length of time in treatment
for SUD in the UK
Substance(s) receiving treatment for (multiple
substances could be indicated)

Median (IQR)

N (%)

45 (53–37)
Male
Female
White
Black
Asian
Other
Employed
Unemployed/sickness
Student
Housewife/husband
Retired
Other
Owner occupied
Rented private
Rented (LA, HA)
Living with parents/relatives
B&B/hotel
Hostel
NFA (living on the streets)
Other

114 (63%)
67 (37%)
133 (73.5%)
14 (7.7%)
6 (3.3%)
28 (15.5%)
55 (30.4%)
105 (58.0%)
5 (2.8%)
5 (2.8%)
6 (3.3%)
2 (1.1%)
17 (9.7%)
53 (30.1%)
73 (41.5%)
17 (9.7%)
2 (1.1%)
5 (2.8%)
6 (3.4%)
3 (1.7%)
5 (15–0.9)

Tobacco
Cannabis
Synthetic cannabinoids
Benzodiazepines
Heroin
Morphine
Codeine
Alcohol
Crack
Cocaine
Amphetamines

20 (11.1%)
28 (15.6%)
2 (1.1%)
19 (10.6%)
98 (54.4%)
13 (7.2%)
14 (7.8%)
71 (39.4%)
52 (28.9%)
47 (26.1%)
10 (5.6%)

HA, housing association; IQR, interquartile range; LA, local authority; NFA, no ﬁxed abode.

participants respectively indicating agreement. The proportion of participants indicating a neutral response
across the survey items averaged 17%.
Negative beliefs. With the exception of two survey items,
less than 30% of participants agreed with negative belief
statements. While more than 50% of participants disagreed
with only three out of eight negative statements, 27% of
participants indicated a neutral response, suggesting greater
levels of ambiguity about objections towards CM.
The most frequently endorsed negative belief statement was that ‘incentives are most useful for short-term
purposes…’ with 38% agreeing with this statement.
Statements pertaining to ethical and moral concerns
were among the least endorsed. Only 11% of participants agreed with the statement ‘incentives are offensive
to me because they are a bribe’. Other statements
expressing ethical concerns about the appropriateness
of incentives (incentives ‘…conﬂicts with my idea of

appropriate treatment’ and ‘it is not right to give incentives to service users for what they should be doing…’)
received modest endorsement, with 26% and 20%
respectively agreeing with these statements.
Statements alluding to the negative side effects of CM
were among the most supported negative items. Twentyeight percent of participants agreed with the statement
‘incentives will stop the service user from realising their
internal motivation to engage in healthy behaviours’. The
second most endorsed negative belief (32%) was that
‘most service users would sell or exchange incentives …
[and] use the money to engage in substance use’.

Acceptability towards CM mechanisms
Table 3 shows the percentages of participants indicating agreement, disagreement or neutral responses to
each individual item.
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Table 2. Percentage of participants agreeing with Provider Survey of Incentives items

Positive beliefs
1
Incentives are worthwhile because they can get
reluctant service users in the door for treatment.
3
Incentives are good for the service user–recovery
worker relationship.
5
Incentives are more likely to have positive effects
on the service user than they are to have negative
effects.
10
I would be in favour of incentives to build healthy
behaviours for service users.
11
Incentives are useful if they reward service users
for fulﬁlling a health-care goal, such as attending
appointments, engaging in physical exercise, or
taking medication as prescribed.
12
An advantage of incentive programs is that they
focus on what is ‘good’ in the service user’s
behaviour (e.g. treatment compliance, drug free
urines/abstinence), not what they did ‘wrong’ (e.g.
not making recommended lifestyle changes).
15
Incentives can be useful whether or not they
address the underlying reasons for engaging in
unhealthy behaviour.
16
Incentives can be useful in building healthy
behaviours (e.g. physical exercise, healthy eating).
17
Incentives can be useful in reducing unhealthy
behaviours (e.g. substance abuse).
18
Overall, I would be in favour of service user
incentive programs.
Negative beliefs
2
It is not right to give incentives to service users for
what they should be doing in the ﬁrst place.
4
Incentives will stop the service user from realising
their internal motivation to engage in healthy
behaviours.
6
It is not useful to give service users incentives
because positive behaviour change will last only as
long as the incentives are given.
7
Giving incentives on a consistent and ongoing
basis conﬂicts with my idea of appropriate
treatment.
8
Incentives are offensive to me because they are a
bribe.
9
There are enough rewards in being healthy;
incentives are not necessary.
13
Most service users would sell or exchange
incentives (e.g. shop vouchers) they receive for
cash, and then use the money to engage in
substance use.
14
Incentives are most useful for short-term purposes
(e.g. encouraging smoking cessation for several
weeks prior to surgery; increasing appropriate use
of antibiotics).

Acceptability of tangible and social incentives. Service
vouchers (e.g. gym passes) were rated as most acceptable (84%), followed by retail vouchers (74%), social

Strongly
disagree

Disagree

Neutral

Agree

Strongly
agree

1.1

6.1

20.4

44.2

28.2

2.8

5.5

26.5

45.3

19.9

0.6

4.4

18.8

53.0

23.2

0.6

6.6

11.0

53.0

28.7

1.1

5.0

7.2

57.5

29.3

1.1

4.4

18.2

51.9

24.3

3.9

17.7

30.9

38.1

9.4

0.6

5.0

12.7

58.0

23.8

1.1

13.3

12.7

53.6

19.3

2.2

6.1

11.0

44.8

35.9

19.3

37.6

23.2

16.6

3.3

10.5

34.3

27.6

21.5

6.1

11.6

37.0

29.3

17.7

4.4

13.3

34.8

26.0

21.5

4.4

29.8

43.1

16.0

8.3

2.8

14.4

39.8

22.7

17.7

5.5

10.5

23.8

34.3

23.8

7.7

5.5

17.1

39.2

32.0

6.1

incentives (71%), prize draws (62%) and clinical privileges (55%). Cash incentives were least acceptable (33%).
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Table 3. Percentage of participants agreeing with additional survey items. Arranged in order of acceptability

Acceptable rewards
Service vouchers (e.g. gym pass, travel card)
Retail vouchers (e.g. supermarket vouchers)
Social incentives (e.g. praise, certiﬁcates)
Prize draw entry (i.e. chance to win a prize)
Clinical privileges (e.g. take-home methadone
doses)
Cash
Acceptable target behaviours
Attendance at the clinic
Alcohol use
Adherence to prescribed medications
Stimulant use (e.g. cocaine, amphetamines)
Nicotine use
Non-prescribed opiate use (e.g. heroin, codeine,
morphine)
Cannabis use
Acceptable monitoring devices
Breathalyser to verify reduced alcohol
consumption
Breath carbon monoxide to verify smoking
cessation
Electronic device (i.e. tablet, computer, mobile
phone) to record attendance at the clinic
Electronic pill dispenser to verify medication
consumption
Acceptable delivery of social reinforcement
In person
By phone call
By text message
Acceptable delivery of tangible reinforcement
In person
On a reloadable debit card (provided by the
clinic)
In the post

Strongly
disagree

Disagree

Neutral

Agree

Strongly
agree

1.7
3.9
2.2
6.1
11.0

3.3
7.7
7.2
8.3
11.6

11.0
14.4
19.3
23.2
22.1

45.3
42.5
40.3
36.5
34.3

38.7
31.5
30.9
26.0
21.0

30.4

21.0

16.0

22.7

9.9

3.3
5.0
3.9
5.5
7.2
5.0

5.0
5.0
6.1
7.2
6.6
7.2

17.1
18.8
21.5
21.0
20.4
22.2

49.7
46.4
46.4
45.9
44.2
42.2

24.9
24.9
22.1
20.4
21.5
23.3

5.0

5.5

27.6

44.2

17.7

1.7

4.4

10.0

58.3

25.6

2.8

6.1

13.3

53.6

24.3

2.8

7.2

12.2

55.2

22.7

2.8

6.6

16.6

53.0

21.0

1.1
3.3
5.5

2.2
5.5
9.9

5.0
14.4
11.6

38.1
44.2
42.0

53.6
32.6
30.9

4.4
7.2

3.9
9.9

12.2
21.0

42.0
39.2

37.6
22.7

7.7

16.6

24.9

32.6

18.2

Acceptability of target behaviours. Most participants
responded that it was acceptable for CM to target nonsubstance use behaviours such as attendance (75%) and
adherence to medications (69%). Levels of acceptability
towards CM targeting substance use varied depending
on substance, from 62% for cannabis use to 71% for
alcohol use. While less than 14% deemed targeting any
substance unacceptable, 22% of participants indicated
neutral responses, suggesting a level of uncertainty.
Acceptability of different modes of delivery. The results
indicate signiﬁcantly high levels of acceptability (78%)
towards the use of electronic devices to monitor behaviour. As many as 81% and 74% thought it appropriate
to monitor a reduction or cessation of substances using
a breathalyser or medication compliance using an electronic pill dispenser. Although the majority deemed it
more acceptable to receive social (92%) and tangible
(80%) incentives in person, remote delivery via phone

call (77%), text message (73%) or reloadable debit
card (62%) were also acceptable. In contrast, delivery
of tangible incentives in the post was acceptable to
only a bare majority (51%).

Associations between participant characteristics and beliefs
regarding CM
No association was found between awareness or experience of CM, age or length of time in treatment and
positive or negative beliefs (Table 4).

Discussion
Our study found that 81% of patients in treatment for
SUD in UK addiction services are in favour of CM
interventions. Our ﬁndings suggest that patients
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Table 4. Chi-squared associations between positive and negative beliefs towards CM and participant characteristics
Positive beliefs towards CM
Agree,
n (%)
Awareness of CM
Yes
57 (97%)
No
118 (97%)
Experience of CM
Yes
14 (100%)
No
161 (96%)
Age, years
20–30
19 (95%)
30–40
43 (98%)
40–50
57 (97%)
50–60
41 (100%)
60–74
11 (85%)
Length of time in treatment
<1 year
53 (95%)
1–5 years
43 (98%)
5–10 years
27 (96%)
10+ years
51 (98%)

Negative beliefs towards CM

Disagree,
n (%)

Chi-square

Agree,
n (%)

Disagree,
n (%)

Chi-square

2 (3%)
4 (3%)

x2(1) = 0.002, P = 0.969

35 (59%)
79 (59%)

24 (41%)
50 (41%)

x2(1) = 0.002, P = 0.969

0 (0%)
6 (4%)

x2(1) = 0.520, P = 0.471

12 (86%)
95 (57%)

2 (14%)
72 (43%)

x2(1) = 4.42, P = 0.035a

x2(4) = 7.476, P = 0.113

11 (55%)
30 (68%)
35 (59%)
19 (46%)
10 (77%)

9 (45%)
14 (32%)
28 (41%)
22 (54%)
3 (23%)

x2(4) = 6.118, P = 0.191

x2(3) = 1.191, P = 0.755

38 (68%)
26 (59%)
18 (64%)
25 (48%)

18 (32%)
18 (41%)
10 (36%)
27 (52%)

x2(3) = 4.706, P = 0.195

1 (5%)
1 (2%)
2 (3%)
0 (0%)
2 (15%)
3 (5%)
1 (2%)
1 (4%)
1 (2%)

a
There was some evidence that people with experience of contingency management differed from those with no experience of
contingency management in terms of their negative beliefs in Chi-square analyses, although not in logistic regression and conﬁdence intervals indicated low precision (odds ratio 4.547, 95% conﬁdence interval 0.987–20.958). CM, contingency
management.

believe CM could be useful in building healthy behaviours (e.g. attendance) and reducing unhealthy
behaviours (e.g. substance use). Although limited
research has been conducted to examine patients’
beliefs towards CM, our ﬁndings are consistent with
those examining acceptability towards study procedures among patients in receipt of CM [15–18].
Among objections commonly held by treatment providers is that it is unethical to ‘pay people for what they
should be doing anyway’ [14], however we found little
support for this concern among participants. While
half of our participants agreed ‘incentives can be useful
whether or not they address the underlying reasons for
engaging in unhealthy behaviours’, a modest proportion agreed that ‘incentives will stop the service user
from realising their internal motivation to engage in
healthy behaviours’. This was one of the biggest concerns among our sample and one that might pose signiﬁcant barriers to the uptake of CM among patients.
Health-care providers also report concern about the
impact CM may have on the therapeutic relationship
[15]. Although some suggest CM can strengthen this
relationship others argue that it could negatively
impact the development and sustainability of it, by
shifting the focus from the treatment needs of the individual to monitoring behaviours and delivery of monetary reward [34]. While we found some uncertainty
reﬂected by around a quarter offering a ‘neutral’

response, 65% agreed that ‘incentives are good for the
service user-recovery worker relationship’. Future
investigations must explore this critical issue and carefully consider the way in which incentives are provided
to participants and by whom.
Our study allowed us to explore patients’ acceptance
of the use of tangible and social incentives. This insight
is key in the development of CM interventions to
ensure the reward is appropriate and meaningful.
While retail and service vouchers were acceptable to
most, 51% of participants disagreed with the use of
cash. Previous research suggests that cash may be
more effective than voucher-based reinforcers and participants utilise their incentives responsibly [35,36].
Therefore, it is essential that objections towards the
use of cash incentives are addressed effectively. However, it is possible that presenting a range of tangible
and social incentives concurrently created a contrast
effect. While a similar effect was found in the original
study utilising the PSI tool [8], and this was considered in the development of the SUSI, future research
should do more to minimise this impact.
Furthermore, moderate levels of support were found
for targeting abstinence, with alcohol use being most
endorsed. Worth noting however, is that around one in
ﬁve patients indicated neutral responses (22%),
suggesting some level of uncertainty. It is plausible to
assume that patients demonstrating negligible
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acceptability towards CM are more likely to report less
support to targeting behaviour change. Despite this
ambiguity, a small number of patients indicated that
targeting any substance would be unacceptable. Conversely, encouraging non-substance use behaviours
were reported to be more acceptable, with more than
two thirds of participants deeming it appropriate. This
is important, as CM targeting these behaviours can have
a positive impact on reducing substance use [37,38].
The empirical ﬁndings from this study are the ﬁrst
to shed light on patients’ attitudes towards the use of
technological devices including mobile telephones to
deliver CM. The ﬁndings allow us to understand how
patients perceive remote applications of CM and their
acceptability towards these modalities which are typically automated with limited human interaction. Our
ﬁndings suggest that patients consider it acceptable to
use devices such as breathalysers to monitor treatment
behaviours or verify a reduction in substance use.
Modest levels of acceptability towards the use of technology (e.g. mobile telephones) to monitor behaviour
and deliver reinforcement were also found. These ﬁndings are pertinent in the development of remote CM
interventions, as they suggest patients’ recognition of
the importance to ensure objective measurement and
veriﬁcation of the target behaviour. With mobile
telephone-delivered CM demonstrating potential effectiveness in encouraging abstinence and 96% of patients
currently owning a mobile telephone, using this platform to extend the reach of CM within a UK setting
may be more possible than ever before.

Study strengths
This study not only provides novel insight into the
beliefs and objections held by patients towards CM,
but sheds light on patients’ acceptance of the use of
remote technological devices to monitor behaviour and
deliver reinforcement. Assessing perceived beliefs
and objections towards technology-based CM among
non-recipients provides an important perspective and
eliminates biases associated with conducting acceptability assessments with individuals already enrolled
and engaging with a CM intervention. Furthermore,
the SUSI tool was developed in collaboration with the
PSI author, selecting items based on their relevance to
a patient population and modifying the language to
ensure appropriate for a UK audience. As the original
PSI consisting of 44 items was deemed too lengthy
and cumbersome for our target group making it difﬁcult to implement, the SUSI consisted of 18 items.
The SUSI tool demonstrated high levels of internal
consistency and reliability, warranting its use and

application for future studies examining beliefs held
regarding CM interventions.

Study limitations
Despite successfully capturing a range of patients receiving treatment for drugs and alcohol, our sample cannot
be representative of all UK patients receiving substance
use treatment and thus caution should be taken when
interpreting ﬁndings. Furthermore, the samples were
those currently in treatment for SUD, indicating some
degree of engagement with their treatment. Future explorations should examine beliefs held among individuals
outside of London and those not in treatment for SUD
who might offer a different perspective.
Our ﬁndings also indicate a high proportion of participants selected a ‘neutral’ response to negative belief
statements, indicating frequent ambiguity. The interpretation of neutral responses presents considerable
challenges as one might select a neutral response when
they believe the question is not relevant to them or
they do not feel they have enough information to make
an informed choice. Another plausible explanation
could be difﬁculty in understanding the terminology
used in the SUSI tool. Although this would not have
disadvantaged the majority, patient consultations in
the development phase could have helped ensure the
SUSI tool was suitable for a range of educational abilities. Furthermore, previous literature has highlighted
the impact limited understanding of CM has on beliefs
and objections among treatment providers [21].
Although our study found no evidence to support the
association between beliefs and experience with CM,
the number of participants with prior experience might
have been too small for differences to be detected.
Further investigations with larger samples sizes would
enable us to explore how beliefs might differ by demographic group. Additionally, it was not possible to
assess associations between substance receiving treatment for and levels of acceptability towards CM, however future research should consider this, given that
treatment outcomes differ by type of substance.

Conclusion
This study is the ﬁrst to assess patients’ beliefs towards
CM and the acceptability of delivering these interventions remotely using technology among patients in
treatment for SUD. These ﬁndings not only highlight
the most prevalent objections and concerns that may
impact upon uptake of CM, but also indicate that most
patients are accepting of these interventions. However,
future research must address several key issues
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highlighted by this study. Addressing objections
towards the use of cash incentives is imperative in
ensuring these interventions are acceptable to the
patient population. Future surveys should consider
the addition of open-ended qualitative questions to
enable participants to indicate their reasoning and
motivations for their particular beliefs and objections
towards CM. Furthermore, future research should utilise larger sample size to examine beliefs held among
other patient groups, including those not in treatment
for SUD; patients outside of London; and those with
prior experience of CM interventions. Despite no association being found between experience of CM and
beliefs held about these interventions, previous literature has indicated the role awareness and experience of
CM plays in generating positive attitudes towards these
interventions and therefore efforts should be made to
promote understanding of these treatments and the
integration of such in UK clinical practice. Finally,
remote CM and mobile CM speciﬁcally, may offer a
potentially useful means of engaging those individuals
who are particularly difﬁcult to treat due to comorbidity and polysubstance use, and therefore their development and implementation within UK drug treatment
services should be given serious consideration.
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